Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus and rheumatoid arthritis.

Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has described polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and gastric inhibitory polypeptide receptor (GIPR) agonists reported to be useful for the treatment of dyslipidemia, hepatic steatosis, metabolic syndrome, obesity and type 2 diabetes.

Amphista Therapeutics Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an F-Box only protein 22 (FBXO22)-binding moiety coupled to a transcriptional enhancer factor TEF (TEAD)-targeting moiety through a linker reported to be useful for the treatment of cancer.

Researchers at Dankook University and Korea University Research & Business Foundation Sejong Campus have identified thiophene derivatives acting as lysine-specific demethylase 4C (KDM4C; GASC-1; JMJD2C) inhibitors reported to be useful for the treatment of Alzheimer’s disease.

Bial-Portela & Ca SA has synthesized orexin OX2 receptor agonists reported to be useful for the treatment of type 1 narcolepsy.

Scientists at Technical Institute of Physics and Chemistry, Chinese Academy of Sciences have disclosed hypocrellin derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of cancer, bacterial infections and fungal infections.

Alicorn Pharmaceutical Co. Ltd. has divulged new DNA polymerase θ (POLθ; POLQ) inhibitors reported to be useful for the treatment of cancer.

Hefei Institutes of Physical Sciences has synthesized new pyrazoleamide compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, Crohn’s, Graves, Parkinson’s disease, ischemia, sepsis, multiple sclerosis and HIV infection.

Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).

Park City Bio LLC has prepared and tested new serotonin receptor agonists reported to be useful for the treatment of pain, inflammation, psychiatric and neurological disorders.